Double-Blind, Placebo-Controlled Trial of Topiramate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: From 40% to 60% of obsessive-compulsive disorder (OCD) patients fail to tolerate or respond to selective serotonin reuptake inhibitors (SSRIs). Preclinical and neuroimaging studies have shown abnormally high glutamatergic concentrations in OCD patients and an association between decreased caudate glutamatergic concentrations and reduced OCD symptom severity after SSRI treatment. Topiramate inhibits glutamatergic conduction. METHOD: Thirty-six adult patients with DSM-IV-defined OCD were randomly assigned to topiramate (n = 18) and placebo (n = 18) groups in this 12-week, double-blind, placebo-controlled, parallel-groups trial. Subjects were taking the maximum SSRI dose they could tolerate for at least 12 weeks and their current dose for at least 6 weeks, which was maintained throughout the study. Primary outcome measures were changes in the Yale-Brown Obsessive Compulsive Scale (YBOCS) total score and compulsions and obsessions subscores. Patients were recruited and followed up between April 1, 2003, and April 13, 2006. RESULTS: Using mixed regression models (time [weeks] × treatment), we found a significant treatment effect on the YBOCS compulsions (P = .014) subscale, but not the obsessions (P = .99) subscale or the total score (P = .11). Over the 12-week trial, the topiramate group (mean endpoint dose = 177.8 ± 134.2 mg/d; range, 50-400 mg/d) showed an average linear decrease of 5.38 points on the compulsions subscale compared to 0.6 points in the placebo group. Thirteen topiramate and 14 placebo subjects completed the study. Topiramate was not well tolerated in this trial: 28% (5/18) of the subjects discontinued the drug for adverse effects, and 39% (7/18) had a dose reduction for this reason. CONCLUSIONS: The results of this first double-blind, placebo-controlled trial of topiramate augmentation for treatment-resistant OCD suggest that topiramate may be beneficial for compulsions, but not obsessions. Modifications in glutamatergic function may be responsible, at least in part, for the improved response in compulsions seen with topiramate. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00211744.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Self-citationAbramowitz, J. S., Taylor, S., & McKay, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60240-3 · Cited by 1,002
Glutamatergic Dysfunction in OCD
Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300733 · Cited by 344
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314
Arnold, P., Rosenberg, D., Mundo, E., Tharmalingam, S., Kennedy, J., & Richter, M. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1847-1 · Cited by 202
Adams, K. H., Hansen, E. S., Pinborg, L. H., Hasselbalch, S. G., Svarer, C., Holm, S., Bolwig, T. G., & Knudsen, G. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005055 · Cited by 147
MOORE, G. J., MACMASTER, F. P., STEWART, C., & ROSENBERG, D. R. (1998) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199806000-00017 · Cited by 85
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Adjunctive topiramate [795-798] 1* Adjunctive IV ketamine [779,780] 2”
BackgroundBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…anticonvulsant augmentation studies indicate that the addition of topiramate to SSRIs reduces the severity of compulsions [I (PCT)] (Berlin et al., 2011), and of obsessive-compulsive symptoms [I (PCT)] (Mowla et al., 2010); and the addition of lamotrigine to SSRIs reduces the…”
BackgroundPittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
“…are more significant than those of some of the other glutamate-modulating agents described here; in the recently-described controlled study, 28% of topiramate-treated patients dropped from the trial due to side effects, and 39% required a dose reduction during the study (Berlin et al., 2011).”
BackgroundEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder
Wu, K., Hanna, G. L., Rosenberg, D. R., & Arnold, P. D. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.007 · Cited by 264
Fontenelle, L. F., Oostermeijer, S., Harrison, B. J., Pantelis, C., & Yücel, M. (2011) · Drugs · doi:10.2165/11591790-000000000-00000 · Cited by 234
Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C., & Bloch, M. H. (2014) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2014.05.006 · Cited by 222
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Use of topiramate in pregnancy and risk of oral clefts
Margulis, A. V., Mitchell, A. A., Gilboa, S. M., Werler, M. M., Mittleman, M. A., Glynn, R. J., & Hernandez-Diaz, S. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.07.008 · Cited by 179
“Off-label uses include conditions that are also prevalent among women of reproductive age: sleep 10,11 and eating disorders, 12 other psychiatric conditions 13,14 and weight loss.”
Fineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
Self-citationPharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Fineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
Bloch, M. H., Green, C., Kichuk, S. A., Dombrowski, P. A., Wasylink, S., Billingslea, E., Landeros-Weisenberger, A., Kelmendi, B., Goodman, W. K., Leckman, J. F., et al. (2013) · Depression and Anxiety · doi:10.1002/da.22103 · Cited by 94
Albert, U., Marazziti, D., Di Salvo, G., Solia, F., Rosso, G., & Maina, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666171222163645 · Cited by 90
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83
“…adult OCD patients Yes Y-BOCS score mean decrease 32.0% in the topi- ramate group vs. 2.4% in the placebo group (p 0.05) Y-BOCS score change: yes Berlin et al., 2011 12 weeks Dose: 50-400 mg/day Adjunctive Initial treatment: SSRI 36 adult OCD patients Yes No significant treatment effect of…”
BackgroundInfluentialPittenger, C., Bloch, M. H., Wasylink, S., Billingslea, E., Simpson, R., Jakubovski, E., Kelmendi, B., Sanacora, G., & Coric, V. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09123 · Cited by 80
A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder
Stein, D. J., Koen, N., Fineberg, N., Fontenelle, L. F., Matsunaga, H., Osser, D., & Simpson, H. B. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0268-9 · Cited by 65
Van Ameringen, M., Simpson, W., Patterson, B., Dell’Osso, B., Fineberg, N., Hollander, E., Hranov, L., Hranov, G., Lochner, C., Karamustafalioglu, O., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113517955 · Cited by 65
Self-citationGlutamatergic agents for OCD and related disorders
Pittenger, C. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0051-8 · Cited by 62
Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder
Grassi, G., Cecchelli, C., Vignozzi, L., & Pacini, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s255375 · Cited by 44
Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
Bandeira, I. D., Lins-Silva, D. H., Cavenaghi, V. B., Dorea-Bandeira, I., Faria-Guimarães, D., Barouh, J. L., Jesus-Nunes, A. P., Beanes, G., Souza, L. S., Leal, G. C., et al. (2022) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000330 · Cited by 39
Sahraian, A., Bigdeli, M., Ghanizadeh, A., & Akhondzadeh, S. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.05.015 · Cited by 28
“Another double-blind, placebo-controlled trial of topiramate augmentation for treatment of resistant OCD showed that it decreased compulsion in patients with OCD (Berlin et al., 2011).”
Background
Metadata
- Authors
- Berlin, H. A., Koran, L. M., Jenike, M. A., Shapira, N. A., Chaplin, W., Pallanti, S., & Hollander, E.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-08-10
- Volume
- 72
- Issue
- 05
- Pages
- 716-721
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2074349347
- Cited by
- 131
- References
- 9
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.